null

null

null

null

null

null

null

null

null

Pre-revenue clinical-stage biotech; minimal debt, primarily equity-financed; ~$150M+ cash runway; 20% rate rise negligibly impacts operations

Low sensitivity; no significant floating-rate debt; higher rates increase opportunity cost of cash reserves and raise future equity dilution risk

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Single-use catheter components from Asia-Pacific manufacturers; specialized RF energy generators from limited EU/US medical device suppliers

Minimal international revenue currently; EU clinical trials ongoing; USD-denominated operations insulate from currency devaluation risk near-term

Primarily US-based operations; EU trial sites in early stage; negligible foreign currency revenue exposure; effectively single-market company

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Likely dependent on one or two specialized endoscopic catheter OEM manufacturers; substitutability is low given FDA device specifications and validation requirements

Medical device/procedure company; cloud dependency is administrative only; 30-day termination disruptive but not existential; data migration feasible

Clinical data management and regulatory submissions may use cloud; secondary impact is compliance workflow disruption, not revenue loss

Moderate API/software coupling risk for clinical data platforms (Veeva, Medidata); switching costs real but manageable; no proprietary API revenue dependency

Revenue model is procedure-based medical device sales; fails Howey Test on all prongs; no securities law risk from primary revenue model

Very High

Handles patient clinical trial data subject to HIPAA, GDPR (EU trials); compliance infrastructure required; moderate exposure, standard for clinical-stage medtech

Low antitrust risk; nascent market in endoscopic metabolic therapy; no dominant market share; limited competitive overlap with established players

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Pre-commercial; ~100% transactional projected (per-procedure device sales post-launch); no recurring subscription revenue model anticipated

Per-procedure single-use catheter consumable sales plus capital equipment placement; classic razor-and-blade medical device monetization model

Procedure-based pricing targeting ~$3,000–$5,000 per Rejuva catheter; must compete with GLP-1 drug costs (~$15,000/year); value-based pricing pressure is significant

Moderate; durable metabolic benefit versus chronic drug dependency is differentiator, but reimbursement uncertainty constrains near-term pricing power

Target 65–75% gross margin typical for single-use catheter consumables at scale; currently pre-revenue with no realized margin

No free-rider problem; procedure requires trained physician and capital equipment; high friction naturally prevents leakage; strong procedural lock-in

Revenue growth sublinear to headcount post-commercialization; consumable sales scale with distributor network, not internal headcount; favorable operating leverage

Marginal cost of growth driven by manufacturing scale and sales force; doubling revenue does not require doubling headcount; classic medtech leverage model

Not applicable; not a franchise model

At 10x scale, CAC must absorb physician training, hospital committee approvals, and reimbursement navigation; sales cycle remains long and capital-intensive

Weak direct network effects; indirect effects possible via clinical evidence accumulation and KOL advocacy; not a platform business

AI displacement risk low; core product is a physical endoscopic procedure; AI may optimize patient selection but cannot replace the device itself

Moderate-low recession resistance; elective metabolic procedures vulnerable to consumer spending cuts and employer benefit reductions; reimbursement critical buffer

Hospitals and ambulatory surgery centers performing bariatric/metabolic procedures; procurement through GPO or direct hospital system contracts

Gastroenterologists and bariatric physicians as procedure adopters; KOL concentration risk in early commercialization phase is significant

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated toward R&D, clinical trials, and manufacturing scale-up; no legacy infrastructure drag; forward-looking deployment consistent with growth-stage biotech

0001572616

GUTS